The effectiveness and tolerability of switching Indian patients from sacubitril/valsartan, ARNI to perindopril in heart failure with reduced ejection fraction. [Efficient study]
Guardado en:
Autores principales: | Pankaj Jariwala, Kartik Jadhav |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c83fceb969274be9a498b3301be5ddb4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Safety and effectiveness of angiotensin receptor-neprilysin inhibitors (ARNI) in patients with heart failure with preserved ejection fraction (HFPEF) – ‘ARNI-preserved’ study
por: Pankaj Jariwala, et al.
Publicado: (2021) -
Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction
por: M Rizzo, et al.
Publicado: (2020) -
Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
por: Mauro Gori, et al.
Publicado: (2021) -
Prescription of Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction Attending an Outpatient Heart Failure Clinic
por: M Rizzo, et al.
Publicado: (2020) -
Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
por: Domingo Pascual-Figal, et al.
Publicado: (2021)